Cytokinetics (CYTK) PT Raised to $48 at JMP Securities

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CME
8. HUMA
9. NVDA
10. INTC

Go back to Cytokinetics (CYTK) PT Raised to $48 at JMP Securities

Cytokinetics (CYTK) PT Raised to $69 at H.C. Wainwright

December 20, 2021 11:44 AM EST

H.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $69.00 (from $62.00) while maintaining a Buy rating.

The analyst commented, "This morning, Cytokinetics and Ji Xing Pharmaceuticals Limited (private) announced an expansion of their existing partnership by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the treatment of HFrEF... More

Cytokinetics (CYTK) Expands Collaboration with JI XING to Include Licensing of Omecamtiv Mecarbil in China

December 20, 2021 7:32 AM EST

Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited (JI XING), a biopharmaceutical company based in Shanghai and backed by RTW Investments, LP (RTW), today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China. In addition to the license and collaboration agreement with JI XING, Cytokinetics has also entered into Common Stock Purchase Agreements that provide for the sale and issuance to entities affiliated with RTW... More